meRfi®-GM
Alzheimer's disease (AD) & Gut microbiota
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Animal studies to date have focused mainly on how gut microbiota alterations affect Ab pathology and not tauopathy and neurodegeneration
Patients with Alzheimer's Disease (AD) are characterized by higher prevalence of SIBO not associated with increased fecal calprotectin level that may be related to [anti-inflammatory effect](brain://Yy7Mk78C…
References (Sources)
- Alzheimer’s disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence
- Bacteroides fragilis lipopolysaccharide and inflammatory signaling in Alzheimer’s disease
- Biotic/abiotic stress-driven Alzheimer’s disease
- Gut microbiome-derived metabolites in Alzheimer's disease: Regulation of immunity and potential for therapeutics
- Neuroinflammation and the gut microbiota: possible alternative therapeutic targets to counteract Alzheimer’s disease?
- The Links Between the Gut Microbiome, Aging, Modern Lifestyle and Alzheimer's Disease
- Western diet as a trigger of Alzheimer’s disease: From metabolic syndrome and systemic inflammation to neuroinflammation and neurodegeneration